10 Cheap Pharmaceutical Stocks to Buy According to Analysts

4. Organon & Co. (NYSE:OGN)

Price Target Upside: 36.13% 

Organon & Co. (NYSE:OGN) is a global healthcare and pharmaceutical company that is primarily focused on improving women’s health and well-being and it stands fourth on our of cheap pharmaceutical stocks. Bacterial vaginosis, breast cancer, contraception, endometriosis, menopause, polycystic ovarian syndrome (PCOS), and postpartum hemorrhage (PPH) are among the topics that are the focus of the company’s portfolio and innovation pipeline. The company offers more than 60 goods and treatments for women’s health, biosimilars, and a large portfolio of well-known drugs in several therapeutic areas.

Organon & Co. (NYSE:OGN) has a solid product portfolio and is constantly looking to improve what it has to offer. Nexplanon, the biggest product of the company, is anticipated to bring in $1 billion by 2025. With the October 2024 acquisition of Dermavant Sciences Ltd., the business expanded its immuno-dermatology portfolio with cutting-edge therapies like VTAMA, opening up new growth prospects. The company recently announced that the FDA had approved VTAMA (tapinarof) cream for the treatment of atopic dermatitis in adults and children two years of age and up.

While promoting expansion, the corporation has also kept operating expenses under control. In 2024, Organon & Co. (NYSE:OGN) wants to generate about $1 billion in free cash flow. The business had already produced around $700 million in free cash flow as of November. Its dividend payments are supported by its robust cash flow, which also gives it the freedom to invest in high-potential assets. In order to demonstrate the company’s dedication to providing value to shareholders while also concentrating on future expansion, the Board of Directors announced a quarterly dividend of $0.28 per share.